2019-05-06 08:00
The study, which evaluated standard hormonal therapies in metastatic breast cancer, used the DiviTum® blood test as a non-invasive tool to monitor therapy efficacy. A total of 244 patients had their blood samples analyzed with DiviTum® and the...
2019-05-02 13:30
In accordance with previously announced information, the board of directors resolved on 9 April 2019 on a new share issue, with deviation from the shareholders' preferential rights, subject to the extraordinary general meeting's subsequent approval...
2019-04-10 14:00
The agreement gives IBL-America non-exclusive rights to sell DiviTum® to pharmaceutical companies, Contract Research Organizations and research institutes in the US. The collaboration will further increase the commercial activities for this customer...
2019-04-09 23:15
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting on Thursday 2 May 2019 at 13.00 pm CET at Baker & McKenzie's premises at Vasagatan 7 in Stockholm. The...
2019-04-09 22:30
The board of directors of Biovica has, based on the authorization given by the extraordinary general meeting, and as communicated in the Company’s press release earlier today, resolved to carry out a directed new share issue of 6,000,000 Class B...
2019-04-09 17:31
Biovica today announces its intention to carry out a directed new share issue of Class B shares of SEK 45-60 million, directed towards qualified investors in Sweden and internationally (the ”Directed New Share Issue”). Biovica has engaged...
2019-04-01 08:00
The patent is a kit-patent that protects against competing companies making copies of Biovicas product. The patent complements previous patent on the US market, which protects the method for the analyzis, making the protection even stronger. The patent...
2019-03-21 08:00
CEO’s comments Continued focus on commercialization of DiviTum® The focus of Biovica’s business plan is commercialization of DiviTum®, which will provide cancer patients with more personalized treatments leading to better outcomes...
2019-03-20 17:00
Below is a summary of the decisions taken at the Extra Shareholder’s Meeting. The Meeting resolved that the Chairman of the Board should be compensated with SEK 200,000 until the next Annual General Meeting. Lars Holmqvist was elected Chairman of...
2019-03-19 08:00
“We are glad to see that there is a demand for DiviTum® on the research market and an interest to include it in clinical trials in order to effectively follow up cancer treatments. We’re pleased that pharma companies see the value of our...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects